ClinicalTrials.gg
RecruitingNCT06268626DETECTRUpdated Apr 16, 2026

Detection of Endometrial Cancer Through Risk Modelling

An observational study in Endometrial Cancer, sponsored by University of British Columbia. Recruiting at 1 site in Canada. Open to female participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-16.

Sponsored by University of British Columbia · Observational

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
1,000
Ages
40 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 128 studies in Endometrial Neoplasms with a site in Canada — 37 open to participants now, 59 under way, 17 of them phase 3. Endometrial Neoplasms · Canada.

Planned enrollment
2nd of 11
1,000 · median 212
Started
2024
with 4 others
Observational
11 of 128
6 open now
Primary completion
2027-01
later than 21 of 58 live
Registered
108th of 128
by date
Lead sponsor
4 of 128
University of British Columbia

Among the 128 studies in Endometrial Neoplasms with a site in Canada, this one is the 2nd largest by planned enrollment of the 11 observational ones that give a count, is one of 5 that started in 2024, is one of 11 observational ones, reaches primary completion later than 21 of the 58 other live ones, and was the 108th registered.

Endometrial Neoplasms

1,429 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

37 of the 128 studies in Endometrial Neoplasms with a site in Canada are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 40 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 128 studies in Endometrial Neoplasms with a site in Canada, or all of them as a file.
02

Study summary

The study goal is to investigate a non-invasive approach to predict endometrial cancer (EC) risk, better understand disease progression and identify opportunities for intervention.

This two-part case-cohort prospective study will recruit patients whose abnormal uterine bleeding is being evaluated via endometrial biopsy. Participants will complete an online health questionnaire, and a subset will be invited to self-collect vaginal samples for sequencing.

Selected sequenced participants will be invited for longitudinal monitoring (questionnaires, wearable fitness tracker) and an additional vaginal self-collection to identify persistent genetic mutations or microbiome alterations 6-8 months later.

Read the detailed description

Purpose:

To improve the prediction of EC and its precursors by integrating data from questionnaires and biological biomarkers obtained from non-invasive tests (vaginal DNA and microbiome swabs, vaginal pH). We also want to better understand pre-malignant disease progression and identify opportunities for earlier intervention.

Hypotheses:

  1. Risk factors in combination with ultrasound data, and patterns of abnormal bleeding are associated with endometrial cancer and its precursors.
  2. Prediction of pathology is improved by including mutation and microbiome data from noninvasive tests combined with traditional risk factors.
  3. Persistence of mutations and microbiome alterations is more common in patients with endometrial hyperplasia than other benign diagnoses and is associated with lifestyle factors.

Justification:

Non-invasive tests and questionnaires may be used to predict onset of endometrial carcinoma or its precursors and can be used to triage those participants with abnormal bleeding who require an endometrial biopsy.

Objectives:

To enhance understanding of the progression of EC and propose non-invasive methods for detection in patients who are experiencing abnormal uterine bleeding and have already been referred to a gynecologist for an endometrial biopsy.

Research Design:

This is a prospective case-cohort study that will recruit n=1000+ participants over the age of 35 years whose abnormal uterine bleeding is being evaluated via endometrial biopsy. Prospective participants will consent to access the information in their medical records, including access to their pathology report. A subset of participants (n=450) will be invited to self-collect vaginal DNA and microbiome samples using swabs and vaginal pH using a litmus kit for sequencing and analysis. A subset of those who retain their uterus (i.e. are not directed to a hysterectomy per standard clinical management) (n=200+), will be invited to take part in longitudinal monitoring using a wearable fitness tracker (Fitbit) and questionnaires, and an additional vaginal self-collection.

03

Conditions studied

  • Endometrial Cancer

Keywords

  • Screening
  • Prevention
  • Women's Health
  • Reproductive health
  • Abnormal Uterine Bleeding
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study investigators will have 10-15 study gynecologists across British Columbia, Canada, who will be recruiting study participants from patients who are referred to them for an endometrial biopsy due to abnormal uterine bleeding. The investigators aim to recruit \~1000 participants in Study Part A in order to achieve their target sample size of n=50 EIN/EC and n=150 EH.

Sequenced participants will be invited to participate in Study Part B/ Longitudinal monitoring and provide additional samples.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Study Part A:

  • 40 years and older
  • Experiencing unexplained abnormal uterine bleeding (i.e., not from IUD, etc.)
  • Have an intact uterus
  • Referred for an endometrial

Study Part B/Longitudinal monitoring:

  • Those selected for sequencing (from Part A) and who retained their uterus.

Exclusion criteria

Exclusion Criteria:

Study Part A:

  • Endometrial sampling, pelvic radiation, or vaginal infection (vaginosis, yeast) in the past 3 months
  • Started hormone therapy (HRT, , IUD) in the past year (with the exception of tamoxifen)
  • Intercourse, vaginal product use, or douching in the past 48 hours

Study Part B/Longitudinal monitoring:

  • Same as Study Part A
  • EC or EIN, or anyone who is recommended a hysterectomy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • EIN/EC BIOPSY RESULT

    Vaginal samples sequenced. Participation ends here.

  • EH BIOPSY RESULT

    Vaginal samples sequenced. Subset invited to move on to longitudinal monitoring and samples sequenced for 6 additional months.

  • NEGATIVE BIOPSY RESULT

    Control for natural and spontaneous changes in vaginal samples sequenced. Random subset selected to move on to longitudinal monitoring and samples sequenced for 6 additional months.

06

What researchers measure

Primary outcomes

  1. Diagnostic Performance of cfDNA Mutation Detection for Endometrial Pathology

    Cell-free DNA (cfDNA) extracted from vaginal swabs will be sequenced to identify endometrial cancer-associated mutations. Diagnostic performance will be evaluated by calculating sensitivity, specificity, accuracy, positive predictive value, and negative predictive value for detecting endometrial pathology, using biopsy-confirmed pathology as the reference standard.

    Time frame: Through study completion, anticipated 1-2 years

  2. Association Between Vaginal Microbiome Profile and Endometrial Pathology

    Vaginal microbiome DNA extracted from swabs will be sequenced and processed into operational taxonomic units (OTUs) using an in-house bioinformatics pipeline. OTUs will be compared across biopsy-confirmed pathology groups and evaluated against previously published microbiome signatures predictive of endometrial cancer.

    Time frame: Through study completion, anticipated 1-2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Pfeiffer RM, Park Y, Kreimer AR, Lacey JV Jr, Pee D, Greenlee RT, Buys SS, Hollenbeck A, Rosner B, Gail MH, Hartge P. Risk prediction for breast, endometrial, and ovarian cancer in white women aged 50 y or older: derivation and validation from population-based cohort studies. PLoS Med. 2013;10(7):e1001492. doi: 10.1371/journal.pmed.1001492. Epub 2013 Jul 30. PubMed 23935463 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Jan 2027, 27 months after the start.

Of 130 non-industry observational studies under Endometrial Neoplasms, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 206. This study's planned 27 months is below that.

Counting every sponsor, half of 150 studies reached it within 105 months; a quarter within 32 and three quarters within 206.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2024
First posted
Feb 20, 2024
StartActual
Oct 10, 2024
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Apr 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06268626
Collaborators
Canadian Institutes of Health Research (CIHR)
Responsible party
Aline Talhouk (Principal Investigator, University of British Columbia) — Principal investigator
First posted
Feb 20, 2024
Start date
Oct 10, 2024
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Apr 16, 2026

Study contacts

Aline Talhouk, PhD
Contact
a.talhouk@ubc.ca
+1 (604) 875-4111 ext. 21365
Jennifer Ellis-White
Contact
jelliswh@student.ubc.ca
+1 (604) 875-4111 ext. 21369
Aline Talhouk, PhD
principal investigator · University of British Columbia
Anna Tinker, MD
principal investigator · University of British Columbia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion